SEC EDGAR · Company announcement
DGX: Other company developments
Filed 8-K for an event or period dated 2026-10-21. Other company developments.
Follow DGX- Became public
- Oct 22, 2026, 6:53 AM EDT
- Event / period date
- Oct 21, 2026
- Collected
- Nov 7, 2026, 9:56 PM EST
Why this is connected
This filing identifies QUEST DIAGNOSTICS INC as the issuer of the security. The company's SEC identifier connects it to DGX.
Source evidence
Read the source excerpt or record
Item 8.01. Other Events. On October 21, 2026, Quest Diagnostics Incorporated (the “Company”) learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up results. The Company promptly initiated its cybersecurity incident response procedures to contain the activity, assess and investigate the nature and scope of the incident and implement appropriate remedial measures. The Company has notified federal law enforcement authorities and engaged external cybersecurity experts to assist in the investigation and response. While the full scope of unauthorized access remains under investigation, at this time the Company believes that an unauthorized party accessed certain patient records. This incident has not materially disrupted the Company’s business operations or its ability to serve patients. The statements in this report which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, the impact of the incident described in this report, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, chan
Congressional trading in DGX
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Oct 30, 2025 · disclosed Aug 5, 2026 · Joint · filed 279 days later
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Oct 30, 2025 · disclosed Aug 5, 2026 · Joint · filed 279 days later
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 30, 2026 · disclosed Jul 21, 2026 · filed 113 days later
Committee overlap: HELP - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
$1K–$15K · Traded Jul 24, 2025 · disclosed Jan 13, 2026 · filed 173 days later
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
$1K–$15K · Traded Apr 28, 2025 · disclosed Jan 13, 2026 · filed 260 days later
- Dec 11, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Nov 3, 2025 · disclosed Dec 11, 2025 · Joint
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.